Atomoxetine as a treatment for attention déficit hiperactivity disorder: a literature review
DOI:
https://doi.org/10.59471/ijhsc2025271Keywords:
Atomoxetine, Attention Deficit Hyperactivity Disorder, Atomoxetine Hydrochloride, Adverse Effects, EfficacyAbstract
Introduction: Attention Deficit Hyperactivity Disorder (ADHD) is an increasingly common neurobiological disorder with some therapeutic variants. Atomoxetine is a non-stimulant, potent and selective inhibitor with a tendency to be used in this condition.
Objective: to analyze the results of Atomoxetine in terms of dependence and effectiveness in the symptomatic control of Attention Deficit Hyperactivity Disorder.
Method: a search for information was carried out in the PubMed database using inclusion and exclusion criteria where 12 articles were analyzed, including case-control studies, clinical studies and randomized controlled trials.
Results: a total of 12 articles were identified, 6 of which provided substantial information on the use of Atomoxetine, effectiveness, and risk/benefit versus placebos and stimulant pharmacotherapy.
Conclusion: Atomoxetine is a safe and effective drug for the treatment of ADHD because of the low risk of dependence and side effects compared to other drugs already in use
References
López-López A, Poch-Olivé ML, López-Pisón J, Cardo Jalón E. Treatment of attention deficit Hyperactivity disorder in routine clinical practice: Retrospective study. Medicina (B. Aires) (Internet). 2019; 79(1 Suppl 1): 68-71.
Yaylacı F, Şahbudak B, Küçük Ö. Spontaneous Ejaculation Induced with Atomoxetine. Psychopharmacol Bull. 2020;50(1):40-43.
Kowalczyk OS, Cubillo AI, Criaud M, et al. Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD. Psychopharmacology (Berl). 2023;240(10):2045-2060. doi:10.1007/s00213-023-06422-7
Atomoxetina en vademecum (Internet). Iqb.es. Disponible en: https://www.iqb.es/cbasicas/farma/farma04/a091.htm
Grimmsmann T, Himmel W. The 10-year trend in drug prescriptions for attention- deficit/Hyperactivity disorder (ADHD) in Germany. Eur J Clin Pharmacol. 2021;77(1):107-115. doi:10.1007/s00228-020-02948-3
Dutta CN, Christov-Moore L, Ombao H, Douglas PK. Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan. Front Hum Neurosci. 2022; 16:938501. doi:10.3389/fnhum.2022.938501
Kok FM, Groen Y, Fuermaier ABM, Tucha O. The female side of pharmacotherapy for ADHD- A systematic literature review. PLoS One. 2020;15(9):e0239257. doi: 10.1371/journal.pone.0239257
Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention- deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007;194(2):197-209. doi:10.1007/s00213-007-0840-x
Sugimoto A, Suzuki Y, Orime N, et al. The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/Hyperactivity disorder: A non- randomized prospective interventional study. Medicine (Baltimore). 2021;100(27):e26552. doi:10.1097/MD.0000000000026552
Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP. L'atomoxétine: un nouveau traitement du trouble déficitaire de l'attention/hyperactivité de l'enfant et de l'adolescent (Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents). Encephale. 2005;31(3):337-348. doi:10.1016/s0013-7006(05)82399-1
Brunkhorst-Kanaan N, Libutzki B, Reif A, Larsson H, McNeill RV, Kittel-Schneider S. ADHD and accidents over the life span - A systematic review. Neurosci Biobehav Rev. 2021;125:582-591. doi:10.1016/j.neubiorev.2021.02.002
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Stefanny Sanchez Vasquez, Marcelo Adrian Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
